Anti-CD46 Antibody-drug Conjugate FOR46 clinical trials
Its developmentBy Fortis Therapeutics and Kyntra Bio, step by step3 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-CD46 Antibody-drug Conjugate FOR46 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CD46 Antibody-drug Conjugate FOR46 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2019 (2)
| Year | Studies |
|---|---|
| 2019 | 2 |
| 2022 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
Fortis Therapeutics, Inc. (2) · Rahul Aggarwal (1) · Kyntra Bio (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Anti-CD46 Antibody-drug Conjugate FOR46.
- Jul 2027FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate CancerPhase 1/2 · Rahul Aggarwal
Studies
Open first, then newest update. How each study uses Anti-CD46 Antibody-drug Conjugate FOR46 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)RecruitingPhase 2Kyntra BioNCT06842498Written as FG-3246
- FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate CancerActive, not recruitingPhase 1/2Rahul AggarwalNCT05011188Written as FOR46
- A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)CompletedPhase 1Fortis Therapeutics, Inc.NCT03575819Written as FOR46
- A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)CompletedPhase 1Fortis Therapeutics, Inc.NCT03650491Written as FOR46